Kozarich John W's Form 4 filing
Ligand Pharmaceuticals Inc (LGND) · filed Jan 6, 2026
- Accession no.
- 0002001011-26-000004
- Filed
- Jan 6, 2026
- Trade date
- Jan 2, 2026
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 5 non-derivative transactions and 0 derivative transactions. Open-market sales total $88.5K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Kozarich John WCIK 0001223000 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 2, 2026 | Common Stock | SSaleDisposed | −21 | $186.59 | −$3,918.39 | 44,100 | Direct | |
| Jan 2, 2026 | Common Stock | SSaleDisposed | −91 | $187.95 | −$17,103.45 | 44,009 | Direct | |
| Jan 2, 2026 | Common Stock | SSaleDisposed | −102 | $188.96 | −$19,273.92 | 43,907 | Direct | |
| Jan 2, 2026 | Common Stock | SSaleDisposed | −207 | $190.27 | −$39,385.89 | 43,700 | Direct | |
| Jan 2, 2026 | Common Stock | SSaleDisposed | −46 | $192.40 | −$8,850.4 | 43,654 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.